

Keynote Speaker

Marcie A. Glicksman, Ph.D.

Vice President of Biology Orig3n, Inc.

Dr. Marcie Glicksman is the Vice President, Biology at Orig3n, Inc.; a new biotech start-up company focused on stem cell models and regenerative medicine. Previously, Dr. Glicksman was co-Director of the Laboratory for Drug Discovery in Neurodegeneration (LDDN), which is focused on accelerating the identification of new therapeutics. Dr. Glicksman has been in the field of drug discovery for more than 20 years, thirteen years in the pharmaceutical industry and then the most recent ten years at LDDN. Previously, she was at the company, Descartes Therapeutics focused on pain therapeutics and Cubist focused on a<mark>nti-infectives. Prior to these po</mark>sitions, she was at DuPont-Merck and at Cephalon, Inc. She has led multiple advanced programs for neurodegenerative diseases including coinventorship of CEP1347, a drug candidate directed at a kinase that has been in Phase III clinical trials. She has also been part of the team to prepare an IND for a drug for neuropathic pain that has just completed Phase II clinical trials. She was elected (2005-2009) to the Board of Directors and served as Chairman of the Board for the Society for Biomolecular Sciences (now Society for Laboratory Automation and Screening). She is on the science advisory board for the Alzheimer's Drug Discove<mark>ry Fou</mark>ndat<mark>ion (ADDF) and the California</mark> Institute for Regenerative Medicine (CIRM), and reviews grants for NIH, Department of Defense, SBIR, the Michael J Fox, Alzheimer's Association, the Canadian Cancer Society, and Rett Foundation. Dr. Glicksman co-founded the Academic Drug Discovery Consortium with three colleagues as a way to build a collaborative network for the academic drug discovery community. Dr. Glicksman co-designed and developed an annual drug discovery course supported by NIH. She also regularly consults and this has included filing an Investigational New Drug application with the FDA, as well as projects involving the development of new technologies. Dr. Glicksman received a bachelor's degree from Brown University and a Ph.D. degree in Neuroscience from Washington University.

Keynote Speaker

Joseph Saseen, Pharm.D., BCPS, BCACP

Professor and Vice Chair, Department of Clinical Pharmacy Professor, Department of Family Medicine University of Colorado Anschutz Medical Campus



Dr. Joseph Saseen is Professor of Clinical Pharmacy and Family Medicine, and is the Vice Chair for the Department of Clinical Pharmacy. He is a clinical pharmacy specialist in family medicine at the University of Colorado and is the program director of a PGY2 Ambulatory Care residency program. Dr. Saseen is a Board Certified Pharmacotherapy Specialist and a Board Certified Ambulatory Care Pharmacist. He is Fellow of the American Society of Health-System Pharmacists, American College of Clinical Pharmacy and National Lipid Association. Dr. Saseen received his Bachelor of Science in pharmacy and Doctor of Pharmacy degrees from the State University of New York at Buffalo and completed a fellowship in ambulatory care research at the University of Colorado Health Sciences Center. Dr. Saseen serves on the board of directors of the National Lipid Association and is a past member and Chair of the Board of Pharmacy Specialties. Dr. Saseen participates in research related to the pharmacotherapy of chronic diseases such as hypertension, dyslipidemia, gout and program grants related to the expansion of clinical services in ambulatory care clinics. Much of his research has used pharmacy and medical claims databases to assess health outcomes.